Innovation in energy is the need of the hour to help protect and advance India's energy security, net-zero ambitions and an environmentally sustainable future as a fast-developing country in a changing world.
Combine that with India's explosive growth as a bioeconomy, and it makes sense to explore indigenous biology-led fueltech to identify next-gen fuels and biofuel alternatives.
CCAMP, in partnership with @MCSquarePlus, has announced the 𝐌𝐂²+ 𝐆𝐫𝐚𝐧𝐝 𝐁𝐮𝐭𝐚𝐧𝐨𝐥 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞 to identify and support indigenous innovations for bio-Iso-Butanol / N-Butanol production through milestone-based grants and equity-free prizes of up to 12.5 Cr INR plus commercialisation pathways with almost all of India's oil and energy PSUs.
Applications are invited from startups, MSMEs, academic and research institutions, corporates and industry R&D teams, and individual innovators/technologists, singly or in consortium.
🔗𝐃𝐞𝐭𝐚𝐢𝐥𝐬: https://t.co/6Bg8FKzPy2
🌐𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐥𝐢𝐧𝐤:
https://t.co/A5oJUQ6SSk
🕔𝐃𝐞𝐚𝐝𝐥𝐢𝐧𝐞: 15th August 2026 (17:00 hrs IST)
#CCAMP #biofuel #energy
@HardeepSPuri@Taslimarif_IND@PetroleumMin@TheSureshGopi@HPCL@CHTMOP@Sea6Energy@shri_sury@PrinSciAdvOff@PrinSciAdvGoI@DBTIndia@IndiaDST@CSIR_IND@startupindia@DPIITGoI@BIRAC_2012@NITIAayog@AIMtoInnovate@rajesh_gokhale@GoI_MeitY@meitystartuphub@thekjgeorge@PriyankKharge@ITBTGoK@Startup_Kar@Ktech_biotech
The first nationwide MC²+ Bio-Iso-Butanol / N-Butanol Grand Challenge is OPEN and now accepting applications!
MC²+ Foundation (@MCSquarePlus), in partnership with C-CAMP, has launched this challenge that will identify and support indigenous innovations for bio-Iso-Butanol / N-Butanol production and its blending with diesel (10–15%) through milestone-based grants and equity-free prizes.
Applications are invited from startups, MSMEs, academic and research institutions, corporates and industry R&D teams, and individual innovators / technologists, singly or in consortium.
🔗Details: https://t.co/nIs81Oggyi
✍️Application link: https://t.co/A5oJUQ6SSk
🕔Deadline: 15th August 2026 (17:00 hrs IST)
📌What's on the offer:
* Facilities & Mentorship
* Funding support (grant pool of upto ₹7.5 crore in aggregate)
* Prize money for best-performing solutions (Up to ₹5 crore in aggregate)
* Pathway to Commercialisation
Apply now!
#CCAMP #biofuel #energy
@HardeepSPuri@Taslimarif_IND@PetroleumMin@TheSureshGopi@HPCL@CHTMOP@Sea6Energy@shri_sury@PrinSciAdvOff@PrinSciAdvGoI@DBTIndia@IndiaDST@CSIR_IND@startupindia@DPIITGoI@BIRAC_2012@NITIAayog@AIMtoInnovate@rajesh_gokhale@meitystartuphub@thekjgeorge@PriyankKharge@ITBTGoK@Startup_Kar@Ktech_biotech
जीवन में हमेशा शांत रहिए, आप
अपने आप को बहुत मजबूत पाएंगे
क्योंकि लोहा जब ठंडा होता है तो
वह बहुत मजबूत होता है, और जब
गर्म होता है तो कोई भी व्यक्ति
उसका आकार बदल सकता है
इसलिए जब भी गुस्सा आए शांत रहें
*स्वस्थ रहें मस्त रहें व्यस्त रहें*
📢𝐖𝐞 𝐚𝐫𝐞 𝐢𝐧𝐯𝐢𝐭𝐢𝐧𝐠 𝐥𝐢𝐜𝐞𝐧𝐬𝐢𝐧𝐠 𝐢𝐧𝐭𝐞𝐫𝐞𝐬𝐭𝐬 —
We are looking for industry partners to scale up a novel immunomodulator in the #respiratory infection space.
Developed and translated by the C-CAMP translation research programme, Respi-Protect helps to prevent and treat respiratory infections such as the flu and COVID-19 through intranasal delivery.
Respi-Protect's USP:
A non-invasive, easily deliverable option for the prevention and treatment of various respiratory infections.
What is the technology?
It is an immunomodulatory peptide-based immune-boosting mechanism with broad-spectrum activity against viruses like Influenza and potentially SARS-CoV-2
How does it work?
Respi-Protect works by activating the innate immune system in the nasal mucosa, which is the initial entry point for respiratory pathogens. This activation is achieved by modulating the TLR2/4 pathways. Studies conducted on animal models of influenza and COVID-19 have shown that Respi-Protect can serve both prophylactically and therapeutically, reducing lung damage and viral titers.
We invite #industry partners and other interested stakeholders to explore partnership opportunities with us.
If you are interested in knowing more about this technology, please reach out to the CCAMP Office of Technology Transfer (#OTT):
📧[email protected], [email protected]@Taslimarif_IND@PrinSciAdvOff@PrinSciAdvGoI@DBTIndia@IndiaDST@BIRAC_2012@SiemensHealth@Boehringer@Novartis@NovartisIndia@biogen@EliLillyandCo@AurigenePharma@sanofi@IndiaSanofi@Cipla_Global@ZydusUniverse @benedicphar
Scientists have created one of the most detailed 3D reconstructions of a human cell (eukaryotic cell) ever produced.
This groundbreaking model, often termed a "Cellular Landscape Cross-Section Through a Eukaryotic Cell," combines data from X-ray tomography, nuclear magnetic resonance (NMR), and cryo-electron microscopy to map molecular structures in extreme detail.
#TechnologyForLicensing
We are looking for industry partners to scale up a novel immunomodulator in the #respiratory infection space.
Developed and translated by the CCAMP translation research programme, Respi-Protect helps to prevent and treat respiratory infections such as the flu and COVID-19 through intranasal delivery.
Respi-Protect's USP: A non-invasive, easily deliverable option for the prevention and treatment of various respiratory infections.
What is the technology?
It is an immunomodulatory peptide-based immune-boosting mechanism with broad-spectrum activity against viruses like Influenza and potentially SARS-CoV-2
How does it work?
Respi-Protect works by activating the innate immune system in the nasal mucosa, which is the initial entry point for respiratory pathogens. This activation is achieved by modulating the TLR2/4 pathways.
Studies conducted on animal models of influenza and COVID-19 have shown that Respi-Protect can serve both prophylactically and therapeutically, reducing lung damage and viral titers.
We invite #industry partners and other interested stakeholders to explore partnership opportunities with us. If you are interested in knowing more about this technology, please reach out to the CCAMP Office of Technology Transfer (#OTT):
📧[email protected], [email protected]
📷080 6718 5322
@Taslimarif@PrinSciAdvOff@PrinSciAdvGoI@DBTIndia@IndiaDST@BIRAC_2012@SiemensHealth@Boehringer@Novartis@NovartisIndia@biogen@EliLillyandCo@AurigenePharma@sanofi@IndiaSanofi@Cipla_Global@ZydusUniverse @benedicphar
The C-CAMP Translation Challenge is now open with 15 industry problems + an open module for all life science proposals.
🧪 Apply by June 9, 2025
🔗 https://t.co/9fBMjgDKic
The 4th call for proposals under the Research Translation Accelerator is now open and is accepting solutions. @CCAMP_India invites proposals from academia that address at least one of the 15 Industry Problem Statements outlined in this call.
🗓️Due Date: 09th June 2025
🖇️Link to apply: https://t.co/1LjpFahyH0
@DrJitendraSingh@rajesh_gokhale
🚨 Deadline Extended till January 25!
Join CCAMP Tech Showcase 5.0 and explore cutting-edge innovations across the Diagnostics, Therapeutics, and Medical Devices sectors.
✅Connect directly with inventors
✅Discover solutions relevant to your organisation's objective.
✅Kickstart collaborations or in-license technologies that fit your strategic interests.
🗓️When? 21 February
📍Where? CCAMP
🔗 Register now:
Inventor: https://t.co/dZ1cGgIc8b
Industry: https://t.co/XT9RbRWRe7
More details: https://t.co/av6zZhSiST
📧 Contact: [email protected], [email protected]
📞 Call us: 08067185322
@Taslimarif@DBTIndia@BIRAC_2012@ITBTGoK@Startup_Kar@Ktech_biotech@AIMtoInnovate@IndiaDST@meitystartuphub@GoI_MeitY@startupindia